Yanbo Zhang

#immunologist #cellbiologist Opinions are mine. Retweets/Likes ≠ endorsements.

[Yanbo Zhang @Yanbo_Z]

https://t.co/jnX5CvWqdy

[ShorterLab @ShorterLab]

Genetically targeted mTORC1 inhibitor reveals transcriptional control by nuclear mTORC1: https://t.co/bqTeyJXOrs

[Ivan Zanoni @Lo_Zanzi]

#EveryCellIsAnImmuneCell! 💥#NewPaperAlert💥 Excited to share our latest review with @agharrison6 about molecular, cellular & #spatial control of the immune response regulated by #stromal, #innate, & #adaptive immune cells in the lymph node! Free link👉 https://t.co/H76GgXLXHs

[David Lagares, PhD, MBA @david_lagares]

Our latest paper is out @ScienceTM! Natural killer cell immunotherapy reverses lung fibrosis by eliminating senescent fibroblasts | Science Translational Medicine https://t.co/YPwY048I3I #Immunotherapy #Fibrosis #Aging #Senescence #NKcell

[Immune Regulation News @Immune_News]

Dr. Shohei Hori and @UTokyo_News_en colleagues show in @ImmunityCP that the master regulator Foxp3 cooperates with or counteracts specific transcription factors to orchestrate diverse cis-regulatory programs across #Treg differentiation states.

📚 https://t.co/zV2SZ2p911

[Dr. John Cush @RheumNow]

Review of Toll-like Receptor Research

A new review on TLRs systematically summarizes 40 years of discoveries in the TLR field, from the initial identification of Toll in Drosophila embryonic development to the current understanding of multilayered regulatory mechanisms that govern TLR signaling.

https://t.co/5yoUqVZjvI

[Nature Reviews Drug Discovery @NatRevDrugDisc]

For readers interested in targeted protein degradation, this Perspective discusses safety considerations for PROTACs and molecular glues that recruit the E3 ligase cereblon to achieve degradation of their target
https://t.co/BRgXcoYMK4
https://t.co/Uq7tp5FgeH

[Eric Topol @EricTopol]

Our best shot for preventing many diseases?
Exercise
A @Cell_Metabolism new review
https://t.co/axi6aUDpZ7

[Yanbo Zhang @Yanbo_Z]

Year One as CEO: What Leadership Actually Feels Like https://t.co/0gr5OxunQ4

[Nature Metabolism @NatMetabolism]

#Throwback

REVIEW | @DrGregSteinberg, @Immunometabolab et al

AMPK at the interface of nutrient sensing, metabolic flux and energy homeostasis
https://t.co/KGtbz8TtTx

[Ohad Hammer @ohadhammer]

Great tables from Wedbush listing small molecule oncology and hemonc drugs ordered by approval date.
I counted ~20 different classes for solid tumors and ~6 for liquid, most revenues are driven by a handful of classes that reached multi billion $ in annual sales (ABL, CDK4/6, EGFR, VEGFR, BTK) over the years.
Next major targets: KRAS, PRMT5, mut PI3K, next gen epigenetics (EZH, KAT)

[Endpoints News @endpts]

Anthropic makes its first $400M biotech bet; Praxis's epilepsy drug hits in early-stage data.
https://t.co/DZpMV8bRgK

[Paras Sharma @paras_biotech]

Biotech IPO Cohorts: Capital, Time & Maturity
(2017-2026)

**Biotech IPOs have evolved from ~$80–100M, ~6-year, Phase 1 companies achieving ~1.5–2.0x re-ratings to ~$500M pvt raisings, ~11-year, Phase 2/3 companies accessing public markets with minimal valuation uplift

[Waggoner Lab @LabWaggoner]

Irisin is an exercise-induced myokine that ameliorates obesity and insulin resistance via adipose tissue IL-33 and regulatory T cells @NatMetabolism @harvardmed
https://t.co/WmsnXinZRX

[Waggoner Lab @LabWaggoner]

Review @CellCellPress @Joseph_C_Wu @Stanford
New approach methodologies for drug discovery
https://t.co/rzwfEvIxkK

[Nature Reviews Drug Discovery @NatRevDrugDisc]

For readers interested in novel drugs for chronic obstructive pulmonary disease, such as AstraZeneca's IL-33 inhibitor tozorakimab, here's a recent review
https://t.co/4UFbeXJJJn
https://t.co/ULV9NhrVMG

[Claudia Jakubzick @claudjak]

Excited to share- Building on our work defining TRMacs heterogeneity, we show that distinct chemokine+ IM subsets and recruited TAM niches shape pro- and anti-tumor immunity within to the TME, while Ag+ moDCs trafficking to LNs dampen DC-based neoAg vac
https://t.co/iYpHv6O1S4

[Nature Biotechnology @NatureBiotech]

Voices of biotech leaders
Nature Biotechnology asks a selection of leaders from across biotech to look at the future of the sector and make some predictions for the coming years https://t.co/jp04YcgXCV

[Livnat Jerby @LivnatJerby]

Excited to share our paper on engineering spatially targeted immune cells is now out in @NatImmunol. https://t.co/pVIt7p3t61

#CRISPR activation screens reveal that engineering metabolite-sensing NK and T cells provides programmable mechanisms to target solid tumors.

Congrats to @komong0702, Mike Tsai, and the team!

Thanks to @ocrahope, @StanfordCancer, @AllenInstitute, @BWFUND, @czbiohub, @genome_gov, Tull Family Foundation, @stanfordcbio, @Stanford Genetics and @StanfordMed for the support.

[nature @Nature]

Nature research paper: Facile induction of immune tolerance by an interleukin-2–TGFβ surrogate agonist

https://t.co/qNTaD6c3Fd